3-Aza-6,8-dioxabicyclo[3.2.1]octanes as new enantiopure heteroatom-rich tropane-like ligands of human dopamine transporter

Bioorganic and Medicinal Chemistry

Volumn 14, Issue 15, 2006, Pages 5110-5120

  Cini, Nicoletta ^a   Danieli, Elisa ^a   Menchi, Gloria ^a   Trabocchi, Andrea ^a   Bottoncetti, Anna ^a   Raspanti, Silvia ^a   Pupi, Alberto ^a   Guarna, Antonio ^a  

^a UNIVERSITY OF FLORENCE   (Italy)

Author keywords

DAT; Scaffold; SERT; Tropane

Indexed keywords

3BETA (4 FLUOROPHENYL) 2BETA TROPANECARBOXYLIC ACID METHYL ESTER; CITALOPRAM; DOPAMINE TRANSPORTER; MONOAMINE; N (3,4 DICHLOROPHENYL) 6,8 DIOXA 3 AZABICYCLO[3.2.1]OCTANE 4 CARBOXYLIC ACID METHYL ESTER; N (4 ACETYLPHENYL) 6,8 DIOXA 3 AZABICYCLO[3.2.1]OCTANE 4 CARBOXYLIC ACID METHYL ESTER; N (4 BROMOPHENYL) 6,8 DIOXA 3 AZABICYCLO[3.2.1]OCTANE 4 CARBOXYLIC ACID METHYL ESTER; N (4 CHLOROPHENYL) 6,8 DIOXA 3 AZABICYCLO[3.2.1]OCTANE 4 CARBOXYLIC ACID METHYL ESTER; N (4 FLUOROPHENYL) 6,8 DIOXA 3 AZABICYCLO[3.2.1]OCTANE 4 CARBOXYLIC ACID METHYL ESTER; N (4 IODOPHENYL) 6,8 DIOXA 3 AZABICYCLO[3.2.1]OCTANE 4 CARBOXYLIC ACID METHYL ESTER; N NAPHTHALEN 2 YL 6,8 DIOXA 3 AZABICYCLO[3.2.1]OCTANE 4 CARBOXYLIC ACID METHYL ESTER; N PHENYL 6,8 DIOXA 3 AZABICYCLO[3.2.1]OCTANE 4 CARBOXYLIC ACID METHYL ESTER; OCTANE; RADIOLIGAND; SEROTONIN; SEROTONIN TRANSPORTER; TRITIUM; UNCLASSIFIED DRUG;

ARTICLE; BINDING AFFINITY; BIOASSAY; DRUG DESIGN; DRUG PURITY; DRUG RECEPTOR BINDING; DRUG SCREENING; DRUG SELECTIVITY; DRUG STRUCTURE; DRUG SYNTHESIS; IC 50; IN VITRO STUDY; STRUCTURE ACTIVITY RELATION; SUBSTITUTION REACTION;

ANIMALS; BICYCLO COMPOUNDS, HETEROCYCLIC; BINDING, COMPETITIVE; CELL LINE; CHO CELLS; CITALOPRAM; COCAINE; CRICETINAE; DOPAMINE PLASMA MEMBRANE TRANSPORT PROTEINS; HUMANS; LIGANDS; MODELS, MOLECULAR; MOLECULAR CONFORMATION; RECOMBINANT PROTEINS; SEROTONIN PLASMA MEMBRANE TRANSPORT PROTEINS; STEREOISOMERISM; STRUCTURE-ACTIVITY RELATIONSHIP; TROPANES;

EID: 33746889018     PISSN: 09680896     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmc.2006.04.019     Document Type: Article

References (55)

1. Hornykiewicz O. Pharmacol. Rev. 18 (1966) 925-961
2. Rowley M., Bristow L.J., and Hutson P.H. J. Med. Chem. 44 (2001) 477-501
3. Nieoullon A. Prog. Neurobiol. 67 (2002) 53-83
4. Castellanos F.X., and Tannock R. Nat. Rev. Neurosci. 3 (2002) 617-628
5. Kaufman M.J., and Madras B.K. Synapse 9 (1991) 43-49
6. Morgan G.F., and Nowotnik D.P. Drug News Perspect. 12 (1999) 137
7. Dougherty D.D., Bonab A.A., Spencer T.J., Rauch S.L., Madras D.K., and Fischman A.J. Lancet 354 (1999) 2132-2133
8. Carroll F.I., Lewin A.H., Boja J.W., and Kuhar M.J. J. Med. Chem. 35 (1992) 969-981
9. Fowler J.S., Volkow N.D., Wang G.J., Gatley S.J., and Logan J. Nucl. Med. Biol. 28 (2001) 561-572
10. Volkow N.D., Gatley S.J., Fowler J.S., Logan J., Fischman M., Gifford A.N., Pappas N., King P., Vitkun S., Ding Y.S., and Wang G.J. Synapse 24 (1998) 399-402
11. Kuhar M.J., Ritz M.C., and Boja J.W. Trends Neurosci. 14 (1991) 299-302
12. Carroll F.I., Gao Y., Rahman M.A., Abraham P., Parham K., Lewin A.H., Boja J.W., and Kuhar M.J. J. Med. Chem. 34 (1991) 2719-2725
13. Carroll F.I. J. Med. Chem. 46 (2003) 1775-1794
14. Carroll F.I., Kotian P., Dehghani A., Gray J.L., Kuzemko M.A., Parham K.A., Abraham P., Lewin A.H., Boja J.W., and Kuhar M.J. J. Med. Chem. 38 (1995) 379-388
15. Carroll F.I., Gray J.L., Abraham P., Kuzemko M.A., Lewin A.H., Boja J.W., and Kuhar M.J. J. Med. Chem. 36 (1993) 2886-2890
16. Holmquist C.R., Keverline-Frantz K.I., Abraham P., Boja J.W., Kumar M.J., and Carroll F.I. J. Med. Chem. 39 (1996) 4139-4141
17. Meltzer P.C., Liang A.Y., and Madras B.K. J. Med. Chem. 37 (1994) 2001-2010
18. Meltzer P.C., Liang A.Y., Brownell A.-L., Elmaleh D.R., and Madras B.K. J. Med. Chem. 36 (1993) 855-862
19. Kozikowski A.P., Saiah M.K.E., Johnson K.M., and Bergmann J.S. J. Med. Chem. 38 (1995) 3086-3093
20. Meltzer P.C., Liang A.Y., and Madras B.K. J. Med. Chem. 39 (1996) 371-379
21. Lewin A.H., Gao Y., Abraham P., Boja J.W., Kuhar M.J., and Carroll F.I. J. Med. Chem. 35 (1992) 135-140
22. Abraham P., Pitner J.B., Lewin A.H., Boja J.W., Kuhar M.J., and Carroll F.I. J. Med. Chem. 35 (1992) 141-144
23. Carroll F.I., Mascarella S.W., Kuzemko M.A., Gao Y., Abraham P., Lewin A.H., Boja J.W., and Kuhar M.J. J. Med. Chem. 37 (1994) 2865-2873
24. Meltzer P.C., Blundell P., Huang H., Liu S., Yong Y.F., and Madras B.K. Bioorg. Med. Chem. 8 (2000) 581-590
25. Milius R.A., Saha J.K., Madras B.K., and Neumeyer J.L. J. Med. Chem. 34 (1991) 1728-1731
26. Singh S. Chem. Rev. 100 (2000) 925-1024
27. Meltzer P.C., Liang A.Y., Blundell P., Gonzalez M.D., Chen Z., Clifford G., and Madras B.K. J. Med. Chem. 40 (1997) 2661-2673
28. Ritz M.C., Cone E.J., and Kuhar M.J. Life Sci. 46 (1990) 635-645
29. Reith M.E.A., Meisler B.E., Sershen H., and Lajtha A. Biochem. Pharmacol. 35 (1986) 1123-1129
30. Clarke R.L., Daum S.J., Gambino A.J., Aceto M.D., Pearl J., Levitt M., Cumiskey W.R., and Bogado E.F. J. Med. Chem. 16 (1973) 1260-1267
31. Madras B.K., Pristupa Z.B., Niznik H.B., Liang A.Y., Blundell P., Gonzales M.D., and Meltzer P.C. Synapse 24 (1996) 340-348
32. Meltzer P.C., Blundell P., Yong Y.F., Zhengming C., George C., Gonzalez M.D., and Madras B.K. J. Med. Chem. 43 (2000) 2982-2991
33. Quirante J., Vila X., Bonjoch J., Kozikowski A.P., and Johnson K.M. Bioorg. Med. Chem. 12 (2004) 1383-1391
34. Guarna A., Guidi A., Machetti F., Menchi G., Occhiato E.G., Scarpi D., Sisi S., and Trabocchi A. J. Org. Chem. 64 (1999) 7347-7364
35. Trabocchi A., Menchi G., Guarna F., Machetti F., Scarpi D., and Guarna A. Synlett (2006) 331-353
36. Bicyclic compounds from Glyceraldehyde and Serine derivatives (BG(g)S(s)). Upper cases refer to the stereoisomer derived from d-glyceraldehyde and l-serine derivatives, whereas lower cases refer to compounds derived from their enantiomers. See:. Trabocchi A., Cini N., Menchi G., and Guarna A. Tetrahedron Lett. 44 (2003) 3489-3492
37. 2, were attempted.
38. Abdel-Magid A.F., Carson K.G., Harris B.D., Maryanoff C.A., and Shah R.D. J. Org. Chem. 61 (1996) 3849-3862
39. Wolfe J.P., Wagaw S., Marcoux J.F., and Buchwald S.L. Acc. Chem. Res. 31 (1998) 805-818
40. Quach T.D., and Batey R.A. Org. Lett. 5 (2003) 4397-4400
41. Lam P.Y.S., Bonne D., Vincent G., Clark C.G., and Combs A.P. Tetrahedron Lett. 44 (2003) 1691-1694
42. Antilla J.C., and Buchwald S.L. Org. Lett. 3 (2001) 2077-2079
43. Wolfe J.P., and Buchwald S.L. Tetrahedron Lett. 38 (1997) 6359-6362
44. In the literature is reported the affinity of new compounds toward DAT and SERT receptors using different biological systems, such as monkey caudate putamen, rat striatum, and HEK cells transfected with hDAT. See, for example: Ref. 27; Ref. 14. Meltzer P.C., Liu S., Blanchette H.S., Blundell P., and Madras B.K. Bioorg. Med. Chem. 10 (2002) 3583-3591
45. This fact does not facilitate the exact comparison of the affinity of different classes of compounds. However in some cases, when the same class is tested in two different systems, a common general trend of variation of the affinity was observed. See:. Dar D.E., Thiruvazhi M., Kitayama S., Kopajtic T.A., Gamliel A., Slusher B.S., Carroll F.I., and Uhl G.R. Eur. J. Med. Chem. 40 (2005) 1013-1021
46. Pristupa Z.B., Wilson J.M., Hoffman B.J., Kish S.J., and Niznik H.B. Mol. Pharmacol. 45 (1994) 125-135
47. Goulet M., Miller G.M., Bendor J., Liu S., Meltzer P.C., and Madras B.K. Synapse 42 (2001) 129-140
48. Wavefunction, Inc., Irvine, CA.
49. Halgren T.A. J. Comput. Chem. 17 (1996) 490-519
50. Halgren T.A. J. Comput. Chem. 17 (1996) 520-552
51. Halgren T.A. J. Comput. Chem. 17 (1996) 553-586
52. Halgren T.A., and Nachbar R.B. J. Comput. Chem. 17 (1996) 587-615
53. Halgren T.A. J. Comput. Chem. 17 (1996) 616-641
54. Dewar M.J.S., Zoebisch E.G., Healy E.F., and Stewart J.J.P. J. Am. Chem. Soc. 107 (1985) 3902-3909
55. Hehre W.J., Radam L., Schleyer P.R., and Pople J.A. Ab initio Molecular Orbital Theory (1986), Wiley, New York